Статті в журналах з теми "EZH2i"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "EZH2i".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Preston, Samuel E. J., Audrey Emond, Filippa Pettersson, Daphné Dupéré-Richer, Madelyn Jean Abraham, Alberto Riva, Mena Kinal, et al. "Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype." Molecular Cancer Therapeutics 21, no. 4 (January 27, 2022): 511–21. http://dx.doi.org/10.1158/1535-7163.mct-21-0216.
Повний текст джерелаZhang, Yiqun, Lanlan Zhou, Safran Howard, Attila Seyhan, and Wafik El-Deiry. "DDRE-16. SYNERGISTIC TUMOR SUPPRESSION FROM COMBINATION OF ONC201 AND EPIGENETIC MODULATORS EZH2 OR HDAC INHIBITOR PROVIDES A NOVEL TREATMENT STRATEGY FOR GBM AND DMG." Neuro-Oncology 22, Supplement_2 (November 2020): ii64—ii65. http://dx.doi.org/10.1093/neuonc/noaa215.261.
Повний текст джерелаKosoff, David, Leigh Ellis, David J. Beebe, and Joshua Michael Lang. "Targeting tumor-associated macrophage (TAM) mediated inhibition of T-cell migration in prostate cancer using epigenetic modifying agents." Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020): 166. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.166.
Повний текст джерелаPawlyn, Charlotte, Michael Bright, Amy Buros, Caleb K. Stein, Zoe Walters, Lauren Aronson, Fabio Mirabella, et al. "Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features." Blood 128, no. 22 (December 2, 2016): 3289. http://dx.doi.org/10.1182/blood.v128.22.3289.3289.
Повний текст джерелаSriramkumar, Shruthi, Tara X. Metcalfe, Tim Lai, Xingyue Zong, Fang Fang, Heather M. O’Hagan, and Kenneth P. Nephew. "Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment." PLOS ONE 17, no. 8 (August 3, 2022): e0271584. http://dx.doi.org/10.1371/journal.pone.0271584.
Повний текст джерелаCarrancio, Soraya, Celia Fontanillo, Ryan Galasso, Martino Colombo, Scott Wood, Carla Guarinos, Alejandro Panjkovich, et al. "Abstract 3932: Pathway interaction and mechanistic synergy of CC-99282, a novel cereblon E3 ligase modulator (CELMoD) agent, with enhancer of zeste homolog 2 inhibitors (EZH2is)." Cancer Research 82, no. 12_Supplement (June 15, 2022): 3932. http://dx.doi.org/10.1158/1538-7445.am2022-3932.
Повний текст джерелаWang, Zhiquan, Justin C. Boysen, Huihuang Yan, Charla R. Secreto, Sameer A. Parikh, Saad S. Kenderian, Wei Ding, Esteban Braggio, Susan L. Slager, and Neil E. Kay. "Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia." Blood 136, Supplement 1 (November 5, 2020): 1. http://dx.doi.org/10.1182/blood-2020-140309.
Повний текст джерелаCannito, Sara, Health Biology, Ornella Cutaia, Carolina Fazio, Maria Fortunata Lofiego, Francesca Piazzini, Laura Solmonese, Luana Calabrò, Michele Maio, and Alessia Covre. "844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A896. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0844.
Повний текст джерелаAoyama, Kazumasa, Makiko Mochizuki-Kashio, Motohiko Oshima, Shuhei Koide, Yaeko Nakajima-Takagi, Mitsutaka Maeda, Goro Sashida, and Atsushi Iwama. "Role of the Polycomb Methyltransferase Ezh1 in Myelodysplastic Syndrome Induced By Ezh2 Insufficiency." Blood 128, no. 22 (December 2, 2016): 1968. http://dx.doi.org/10.1182/blood.v128.22.1968.1968.
Повний текст джерелаTanaka, Satomi, Goro Sashida, Satoru Miyagi, Koutaro Yokote, Chiaki Nakaseko, and Atsushi Iwama. "Ezh2 Plays a Critical Role in the Progression of MLL-AF9-Induced Acute Myeloid Leukemia." Blood 118, no. 21 (November 18, 2011): 57. http://dx.doi.org/10.1182/blood.v118.21.57.57.
Повний текст джерелаVo, Ha V., Qing Zeng, David A. Barbie, Prafulla C. Gokhale, Elizabeth Adams, Cloud P. Paweletz, and Elena Ivanova. "Abstract 3264: Ex vivo treatment in high grade serous ovarian cancer demonstrates the benefit of EZH2 inhibition in combination with standard therapy." Cancer Research 82, no. 12_Supplement (June 15, 2022): 3264. http://dx.doi.org/10.1158/1538-7445.am2022-3264.
Повний текст джерелаFiorentino, Francesco Paolo, Irene Marchesi, Christoph Schröder, Ronny Schmidt, Jun Yokota, and Luigi Bagella. "BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells." International Journal of Molecular Sciences 21, no. 24 (December 16, 2020): 9595. http://dx.doi.org/10.3390/ijms21249595.
Повний текст джерелаFang, Xin, Nan Ni, Xiaofang Wang, Yanan Tian, Ivan Ivanov, Monique Rijnkels, Kayla J. Bayless, John P. Lydon, and Qinglei Li. "EZH2 and Endometrial Cancer Development: Insights from a Mouse Model." Cells 11, no. 5 (March 7, 2022): 909. http://dx.doi.org/10.3390/cells11050909.
Повний текст джерелаHasegawa, Nagisa, Goro Sashida, Motohiko Oshima, Hirotaka Matsui, Atsunori Saraya, Changshan Wang, Tomoya Muto, Chiaki Nakaseko, Koutaro Yokote, and Atsushi Iwama. "Combinatorial Epigenetic Aberration Propagates in Myelodysplastic Syndrome in the Setting of Concurrent Loss of Tet2 and Ezh2." Blood 126, no. 23 (December 3, 2015): 712. http://dx.doi.org/10.1182/blood.v126.23.712.712.
Повний текст джерелаMuto, Tomoya, Goro Sashida, Motohiko Oshima, George R. Wendt, Makiko Mochizuki-Kashio, Masashi Sanada, Satoru Miyagi, et al. "Concurrent Loss Of Ezh2 and Tet2 Cooperates In The Pathogenesis Of Myelodysplastic Disorders,." Blood 122, no. 21 (November 15, 2013): 480. http://dx.doi.org/10.1182/blood.v122.21.480.480.
Повний текст джерелаAdamik, Juraj, Jixin Ding, Wei Zhao, Peng Zhang, Quanhong Sun, G. David Roodman, and Deborah Lynn Galson. "LIM-Domain Protein Ajuba Is a Required Co-Factor for Gfi1-Induced Epigenetic Switch Regulating Runx2 Repression in Multiple Myeloma-Exposed Pre-Osteoblasts." Blood 126, no. 23 (December 3, 2015): 4216. http://dx.doi.org/10.1182/blood.v126.23.4216.4216.
Повний текст джерелаZhang, Yiqun, Lanlan Zhou, Howard Safran, Robyn Borsuk, Rishi Lulla, Nikos Tapinos, Attila A. Seyhan, and Wafik S. El-Deiry. "EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG." Neoplasia 23, no. 8 (August 2021): 792–810. http://dx.doi.org/10.1016/j.neo.2021.06.007.
Повний текст джерелаSimon, Camille, Jalila Chagraoui, Jana Krosl, Josee Hebert, and Guy Sauvageau. "Ezh2 Is An Essential Regulator Of T-Cell Development and Oncogenic Transformation." Blood 122, no. 21 (November 15, 2013): 3729. http://dx.doi.org/10.1182/blood.v122.21.3729.3729.
Повний текст джерелаHasegawa, Nagisa, Goro Sashida, Motohiko Oshima, Hirotaka Matsui, Changshan Wang, Tomoya Muto, Chiaki Nakaseko, Kotaro Yokote, and Atsushi Iwama. "The Biological Function of DNA Hypermethylation in Murine MDS Model Lacking Tet2 and Ezh2." Blood 124, no. 21 (December 6, 2014): 4596. http://dx.doi.org/10.1182/blood.v124.21.4596.4596.
Повний текст джерелаAdamik, Juraj, Rebecca Silbermann, Konstantinos Lontos, Peng Zhang, Quanhong Sun, Deborah Lynn Galson, and G. David Roodman. "EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability." Blood 128, no. 22 (December 2, 2016): 3247. http://dx.doi.org/10.1182/blood.v128.22.3247.3247.
Повний текст джерелаGrzenda, Adrienne, Gwen Lomberk, Phyllis Svingen, Angela Mathison, Ezequiel Calvo, Juan Iovanna, Yuning Xiong, William Faubion та Raul Urrutia. "Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression". Epigenetics & Chromatin 6, № 1 (2013): 3. http://dx.doi.org/10.1186/1756-8935-6-3.
Повний текст джерелаHuang, Xian-Ju, Xuguang Wang, Xueshan Ma, Shao-Chen Sun, Xiaolong Zhou, Chengcheng Zhu, and Honglin Liu. "EZH2 is essential for development of mouse preimplantation embryos." Reproduction, Fertility and Development 26, no. 8 (2014): 1166. http://dx.doi.org/10.1071/rd13169.
Повний текст джерелаNaimo, Giuseppina Daniela, Maria Elena Gonzalez, Shilpa Reddy Tekula, Jessica Camille Gauss, Loredana Mauro, Sebastiano Andò, and Celina Graciela Kleer. "Abstract P5-12-05: Novel pEZH2 T367-PRC2 interaction and methyltransferase activity in the nuclear and cytoplasmic fractions of breast cancer cells." Cancer Research 82, no. 4_Supplement (February 15, 2022): P5–12–05—P5–12–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-12-05.
Повний текст джерелаLi, Boheng, Dennis Kappei, Junli Yan, Pieter Eichhorn, Siok Bian Ng, and Wee Joo Chng. "Overexpressed Melk Promotes the Stability of EZH2 through Phosphorylation in Natural Killer/T Cell Lymphoma (NKTL)." Blood 132, Supplement 1 (November 29, 2018): 2858. http://dx.doi.org/10.1182/blood-2018-99-110758.
Повний текст джерелаKotz, Joanne. "EZH2 moves." Science-Business eXchange 5, no. 41 (October 2012): 1072. http://dx.doi.org/10.1038/scibx.2012.1072.
Повний текст джерелаDale, Brandon, Chris Anderson, Kwang-su Park, H. Ümit Kaniskan, Xufen Yu, and Jian Jin. "Abstract 2922: Targeting triple negative breast cancer with a VHL recruiting EZH2 protein degrader." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2922. http://dx.doi.org/10.1158/1538-7445.am2022-2922.
Повний текст джерелаPapakonstantinou, Nikos, Stavroula Ntoufa, Elisavet Chartomatsidou, Andreas Agathangelidis, Tzeni Karamanli, Achilles Anagnostopoulos, Paolo Ghia, Richard Rosenquist, Chrysoula Belessi та Kostas Stamatopoulos. "Overexpression of the Histone Methyltransferase ΕΖΗ2 in Chronic Lymphocytic Leukemia Confers Protection from Apoptosis and Is Linked to Clinical Aggressiveness". Blood 124, № 21 (6 грудня 2014): 1956. http://dx.doi.org/10.1182/blood.v124.21.1956.1956.
Повний текст джерелаPerez-Ladaga, Albert, Huafeng Xie, Stuart H. Orkin, David B. Sykes, Benjamin L. Ebert, and Rafael Bejar. "Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression." Blood 126, no. 23 (December 3, 2015): 4112. http://dx.doi.org/10.1182/blood.v126.23.4112.4112.
Повний текст джерелаShimizu, Takafumi, Hui Hao-Shen, Lucia Kubovcakova, Pontus Lundberg, Stephan Dirnhofer, Stuart H. Orkin, Jean Grisouard, et al. "JAK2V617F and Loss of Ezh2 in Hematopoietic Cells Contribute Synergistically to Myeloproliferative Neoplasm Initiation Potential, and Accelerate Progression of Disease." Blood 124, no. 21 (December 6, 2014): 158. http://dx.doi.org/10.1182/blood.v124.21.158.158.
Повний текст джерелаBasheer, Faisal, George Giotopoulos, Eshwar Meduri, Haiyang Yun, Milena Mazan, Daniel Sasca, Paolo Gallipoli, et al. "Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML." Journal of Experimental Medicine 216, no. 4 (March 19, 2019): 966–81. http://dx.doi.org/10.1084/jem.20181276.
Повний текст джерелаBae, An-Na, Soo-Jung Jung, Jae-Ho Lee, Hyunsu Lee, and Seung Gyu Park. "Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy." Medicina 58, no. 2 (January 20, 2022): 155. http://dx.doi.org/10.3390/medicina58020155.
Повний текст джерелаStomper, Julia, Ruth Meier, Tobias Ma, Dietmar Pfeifer, Annette Schmitt-Graeff, and Michael Lübbert. "Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients." Blood 134, Supplement_1 (November 13, 2019): 1422. http://dx.doi.org/10.1182/blood-2019-128231.
Повний текст джерелаWei, Yue, Yu Jia, Hong Zheng, Hui Yang, Rui Chen, Hui Wang, Xia Wang, and Guillermo Garcia-Manero. "Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS)." Blood 122, no. 21 (November 15, 2013): 2805. http://dx.doi.org/10.1182/blood.v122.21.2805.2805.
Повний текст джерелаSahasrabuddhe, Anagh A., Xiaofei Chen, Thirunavukkarasu Velusamy, Fuzon Chung, Megan S. Lim, and Kojo S. J. Elenitoba-Johnson. "A Novel Non-Canonical Phosphodegron Regulates EZH2 Proteasomal Degradation and H3K27 Trimethylation Activity in Hematopoietic Malignancies." Blood 124, no. 21 (December 6, 2014): 1678. http://dx.doi.org/10.1182/blood.v124.21.1678.1678.
Повний текст джерелаGupta, Mamta, Christos Demosthenous, Mary J. Stenson, and Tammy Price-Troska. "Oncogenic Role of Chromatin Modifier Polycomb Repressive Complex-2 in Mantle Cell Lymphoma." Blood 132, Supplement 1 (November 29, 2018): 1582. http://dx.doi.org/10.1182/blood-2018-99-118957.
Повний текст джерелаJiao, Lianying, Murtada Shubbar, Xin Yang, Qi Zhang, Siming Chen, Qiong Wu, Zhe Chen, Josep Rizo, and Xin Liu. "A partially disordered region connects gene repression and activation functions of EZH2." Proceedings of the National Academy of Sciences 117, no. 29 (July 6, 2020): 16992–7002. http://dx.doi.org/10.1073/pnas.1914866117.
Повний текст джерелаAppelmann, Iris, Claudio Scuoppo, Vishal Thapar, Daniela Ledezma, Amaia Lujambio, Scott W. Lowe, and Agustin Chicas. "Suppression of EZH2 Accelerates MYC-Driven Lymphomagenesis By Inhibition of Apoptosis." Blood 124, no. 21 (December 6, 2014): 3009. http://dx.doi.org/10.1182/blood.v124.21.3009.3009.
Повний текст джерелаChng, Wee-Joo, Junli Yan, Siok-Bian NG, Jim Tay, Baohong Lin, Tze-Loong Koh, Joy Tan, et al. "EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma." Blood 120, no. 21 (November 16, 2012): 3498. http://dx.doi.org/10.1182/blood.v120.21.3498.3498.
Повний текст джерелаMochizuki, Daiki, Yuki Misawa, Hideya Kawasaki, Atsushi Imai, Shiori Endo, Masato Mima, Satoshi Yamada, Takuya Nakagawa, Takeharu Kanazawa, and Kiyoshi Misawa. "Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation." International Journal of Molecular Sciences 19, no. 12 (November 22, 2018): 3707. http://dx.doi.org/10.3390/ijms19123707.
Повний текст джерелаSwords, Ronan T., Aymee Perez, Ana Rodriguez, Justin M. Watts, Tino Schenk, Fernando Vargas, Roy Elias, and Arthur Zelent. "In Acute Myeloid Leukemia (AML), Targeting the Histone Methyltransferase EZH2 Promotes Differentiation, Impairs Clonogenic Survival and Augments the Anti-Leukemic Effects of the Retinoid, All-Trans-Retinoic Acid (ATRA)." Blood 126, no. 23 (December 3, 2015): 3786. http://dx.doi.org/10.1182/blood.v126.23.3786.3786.
Повний текст джерелаTomioka, Takahisa, Goro Sashida, Kotaro Shide, Kazuya Shimoda, Naoto Yamaguchi, and Atsushi Iwama. "Ezh2 Loss Accelerates JAK2V617F-Driven Primary Myelofibrosis." Blood 122, no. 21 (November 15, 2013): 110. http://dx.doi.org/10.1182/blood.v122.21.110.110.
Повний текст джерелаBai, Bing, Ying Liu, Xue-Mei Fu, Hai-Yan Qin, Gao-Kai Li, Hai-Chen Wang та Shi-Long Sun. "Dysregulation of EZH2/miR-138-5p Axis Contributes to Radiosensitivity in Hepatocellular Carcinoma Cell by Downregulating Hypoxia-Inducible Factor 1 Alpha (HIF-1α)". Oxidative Medicine and Cellular Longevity 2022 (29 серпня 2022): 1–22. http://dx.doi.org/10.1155/2022/7608712.
Повний текст джерелаZhang, Xingli, Yan Wang, Jia Yuan, Ni Li, Siyu Pei, Jing Xu, Xuan Luo, et al. "Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3." Journal of Experimental Medicine 215, no. 5 (April 6, 2018): 1365–82. http://dx.doi.org/10.1084/jem.20171417.
Повний текст джерелаMurashima, Akihiro, Keiko Shinjo, Keisuke Katsushima, Tetsuo Onuki, Yasumitsu Kondoh, Hiroyuki Osada, Noritaka Kagaya, et al. "Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay." Journal of Biochemistry 166, no. 1 (January 25, 2019): 41–50. http://dx.doi.org/10.1093/jb/mvz007.
Повний текст джерелаXie, Huafeng, Cong Peng, Jun Qi, Giullia Cheloni, Partha Das, Jialiang Huang, Minh Nguyen, Shaoguang Li, James E. Bradner, and Stuart H. Orkin. "Eradication of Chronic Myelogenous Leukemia By Inactivation of the Polycomb Group Protein EZH2." Blood 124, no. 21 (December 6, 2014): 778. http://dx.doi.org/10.1182/blood.v124.21.778.778.
Повний текст джерелаLi, Boheng, Junli Yan, Tae-Hoon Chung, Pei Tsung Lee, and Wee Joo Chng. "Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL)." Blood 128, no. 22 (December 2, 2016): 1773. http://dx.doi.org/10.1182/blood.v128.22.1773.1773.
Повний текст джерелаIzsak, Allison, Keith Michael Giles, Kevin Paul Lui, Sarah A. Weiss, Una Moran, Eleazar Vega-Saenz de Miera, Jennifer Stein, et al. "Targeting EZH2 in acral lentiginous melanoma (ALM)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 9534. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9534.
Повний текст джерелаYang, Yue, Hajime Akada, Dipmoy Nath, Robert E. Hutchison, and Golam Mohi. "Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice." Blood 124, no. 21 (December 6, 2014): 159. http://dx.doi.org/10.1182/blood.v124.21.159.159.
Повний текст джерелаJacobsen, Jennifer Andrene, Jennifer Woodard, and Barbara L. Kee. "EZH2 regulates cell cycle and survival in B and T lymphocyte progenitors." Journal of Immunology 196, no. 1_Supplement (May 1, 2016): 122.4. http://dx.doi.org/10.4049/jimmunol.196.supp.122.4.
Повний текст джерелаKawabata, Kimihito Cojin, Daichi Inoue, Jiro Kitaura, Yuka Harada, Susumu Goyama, Hironori Harada, Hiroyuki Aburatani, and Toshio Kitamura. "A Patient-Derived EZH2 Mutant Induces MDS-like Diseases with Derepressed ABCG2 Expression in Mice." Blood 126, no. 23 (December 3, 2015): 4116. http://dx.doi.org/10.1182/blood.v126.23.4116.4116.
Повний текст джерела